Survival in Epithelioid Malignant Pleural Mesothelioma

Dr. Nicholas Vogelzang, a physician from the Comprehensive Cancer Center of Nevada in Las Vegas, shares results of his study appearing in the August 2018 issue of Mayo Clinic Proceedings, which, using data collected from the clinical trial that led to the approval of cisplatin and pemetrexed, demonstrated that tumor shrinkage could be used as a reliable measure for treatment success for both increased survival and length of time for disease progression in patient with epithelioid malignant pleural mesothelioma. Available at: mayocl.in/2lQuqGr